Tracers / [111In]BQ7859
[111In]BQ7859
Also written as [In-111]In-BQ7859
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Glu-urea-Lys PSMA-targeting urea-based radioligand with NOTA chelator
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 35631684
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 98.9 ± 0.6% | — | BQ7859 (Glu-urea-Lys-2-naphthyl-L-alanine-L-Tyr-8Aoc-Lys(NOTA)-acetamide) | 35631684 2022 Pharmaceutics The reaction mixture was left for 30 min at 85 °C. — radiolabelled with indium-111, with an average yield of 98.9 ± 0.6% (Table 2) |
Need this precursor?We can point you to suppliers for [111In]BQ7859, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35631684. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35631684: 'BQ7859 (Glu-urea-Lys-2-naphthyl-L-alanine-L-Tyr-8Aoc-Lys(NOTA)-acetamide)'.